Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antitope Ltd.

Division of Abzena Ltd./PolyTherics Ltd.
www.antitope.co.uk

Latest From Antitope Ltd.

Device/Diagnostics Quarterly Deal Statistics, Q3 2014

Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.

Medical Device Deals

Start-Up Quarterly Statistics, Q3 2014

Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.

BioPharmaceutical Medical Device

Abzena Is New Identity For PolyTherics-Antitope; Includes Cambridge HQ

Following last year’s merger of PolyTherics and Antitope, the provider of services to improve biopharmaceutical products has settled on Cambridge in the U.K. for its HQ, while a new holding structure hints at more M&A to come.

BioPharmaceutical United Kingdom

Recent Financings Of Private Companies, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Abzena Ltd.
  • Senior Management
  • Matthew Baker, PhD, CEO & CSO
    Neil Butt, PhD, VP, Bus. Dev.
  • Contact Info
  • Antitope Ltd.
    Phone: (0) 1223 496190
    Babraham Research Campus
    Babraham
    Cambridge, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register